[治疗有认知和行为障碍的儿童的黑激素和记忆素组合 (Miladean) 的临床经验]
A V Goryunov1, M A Morozova1, A A Koval-Zaytsev1
1Mental Health Research Center, Moscow, Russia.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|March 5, 2026
概括
这项试点研究表明,米拉丁 (Miladean) 是一种黑激素和记忆素的组合,可能会改善有行为和认知障碍的儿童的ADHD症状和睡眠质量. 需要进一步的研究来证实这些初步发现.
科学领域:
- 儿科精神病学 儿科精神病学
- 神经药理学神经药理学
- 儿童心理学 儿童心理学
背景情况:
- 患有高动态行为障碍,精神分裂型障碍和精神分裂症的儿童经常表现出认知和行为障碍.
- 目前的治疗方案可能无法完全解决这些复杂的症状,需要新的治疗方法.
研究的目的:
- 评估米拉迪安 (美拉和美曼丁) 作为儿童和青少年认知和行为障碍的补充疗法的疗效和安全性.
- 评估米拉迪安对ADHD症状,睡眠质量和认知功能的影响.
主要方法:
- 一项开放式,单臂试点研究,涉及20名患有诊断疾病的儿科患者 (8-15岁).
- 患者除了稳定背景治疗外,还接受了米拉迪安 (睡前下口服2片) 8周.
- 使用认知测试 (雷文的渐进矩阵,Stroop,Go/No-Go),睡眠质量问卷 (斯皮格尔尺度) 和ADHD症状尺度 (SNAP-IV) 来测量结果.
主要成果:
- 米拉迪安显示出良好的安全性和耐受性.
- 观察到不注意和过度活跃-冲动性症状 (SNAP-IV) 的统计学显著减少 (p<0.001).
- 睡眠质量 (p=0.002) 和反应速度 (去/不去任务,p=0.001-0.033) 显著改善,智力得分有所改善 (p=0.067-0.077).
结论:
- 初步数据表明,米拉迪安可能有效地改善不同诊断类别儿童的认知和行为障碍.
- 这些发现支持需要进行更大规模的双盲,安慰剂对照试验,以确认米拉迪安的疗效.
更多相关视频
04:33Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.6K
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
10.3K
相关概念视频
01:19Management of Insomnia
744
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
744
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
765
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
765
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
729
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
729
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K